Biblio

Deschamps L., Benhamou J., Sugier P.E, Vergier B., Pham-Ledard A., Carlotti A., Avril M., Ortonne N., Zehour O., Durlach A. et al..  2019.  Analysis of mTOR CXCR4 and PD-1 checkpoint pathways in Merkel cell neuroendocrine carcinomas: correlations with prognosis and viral status. VIRCHOWS ARCHIV. 475:S108.

Badrignans M., Tournier B., Jeudy G., Dalac S., Chapusot C., Martin L., Aubriot-Lorton M..  2019.  Assessment of circulating tumour cells and circulating cell-free DNA in patients with metastatic melanoma. VIRCHOWS ARCHIV. 475:S27.

Badrignans M., Tournier B., Jeudy G., Dalac S., Chapusot C., Martin L., Aubriot-Lorton M..  2019.  Assessment of circulating tumour cells and circulating cell-free DNA in patients with metastatic melanoma. VIRCHOWS ARCHIV. 475:S27.

Kandel M., Allayous C., Dalle S., Mortier L., Dalac S., Dutriaux C., Leccia M., Guillot B., Saiag P., Lacour J. et al..  2018.  ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH METASTATIC MELANOMA IN REAL CLINICAL PRACTICE IN FRANCE. VALUE IN HEALTH. 21:S13.

Hober C., Fredeau L., A. Ledard P, Boubaya M., Herms F., Aubin F., Benetton N., Dinulescu M., Jannic A., Cesaire L. et al..  2020.  Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience. ANNALS OF ONCOLOGY. 31:S737.

Dobos G., de Masson A., Ram-Wolff C., Beylot-Barry M., Pham-Ledard A., Ortonne N., Ingen-Housz-Oro S., Battistella M., d'Incan M., Rouanet J. et al..  2021.  Changes in the Epidemiology of primary cutaneous Lymphoma: an Analysis of 8593 Patients from the French Register of Cutaneous Lymphomas (GFELC). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 19:11.

Monnet P., Herms F., Djermane M., Dalac S., Dereure O., Dreno B., Beylot-Barry M., Mortier L., Basset-Seguin N..  2022.  Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors. BRITISH JOURNAL OF DERMATOLOGY. 186:579-581.

Dalac S., Sigal L., Addala A., Chahim M., Faivre-Carrere C., Lemdjadi Z., Bohbot S..  2016.  Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. JOURNAL OF WOUND CARE. 25:531-538.

Kandel M., Bardet A., Dalle S., Mortier L., Guillot B., Dutriaux C., Leccia M.T, Dalac S., Montaudie H., Saiag P. et al..  2019.  COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE. VALUE IN HEALTH. 22:S454-S455.

Kandel M., Bardet A., Dalle S., Mortier L., Guillot B., Dutriaux C., Leccia M.T, Dalac S., Montaudie H., Saiag P. et al..  2019.  COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE. VALUE IN HEALTH. 22:S454-S455.

Kandel M., Bardet A., Dalle S., Mortier L., Guillot B., Dutriaux C., Leccia M.T, Dalac S., Montaudie H., Saiag P. et al..  2019.  COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF-MUTATED METASTATIC MELANOMA PATIENTS IN REAL LIFE IN FRANCE. VALUE IN HEALTH. 22:S450.

Seris A., Battistella M., Beylot-Barry M., Dalle S., Mortier L., Lebbe C., Blom A., Neidhart-Berard E-M, Kramkimel N., Dupuy A. et al..  2019.  Creation, implementation and objectives of CARADERM, a national network for rare skin carcinomas - Adnexal neoplasm part. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 146:704-710.

Borget I, Dalle S., Leccia M., Dutriaux C., Stoebner P., Dalac S., Aubin F., Saiag P., Lacour J.P, Lesimple T. et al..  2016.  EFFECTIVENESS AND SAFETY OF VEMURAFENIB AS MONOTHERAPY IN UNRESECTABLE OR METASTATIC MELANOMA FROM AN ACADEMIC DATABASE: REAL WORLD DATA TO STRENGTHEN EVIDENCE FOR PAYER. VALUE IN HEALTH. 19:A762-A763.

Dobos G., de Masson A., Ram-Wolff C., Beylot-Barry M., Pham-Ledard A., Ortonne N., Ingen-Housz-Oro S., Battistella M., d'Incan M., Rouanet J. et al..  Submitted.  Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. BRITISH JOURNAL OF DERMATOLOGY.

Kandel M., Allayous C., Dalle S., Dalac S., Saiag P., Lacour J., Descamps V, Maubec E., Lesimple T., Stoebner P. et al..  2017.  ESTIMATION OF THE COST OF METASTATIC MELANOMA IN FRANCE USING MELBASE DATA. VALUE IN HEALTH. 20:A427-A428.

Guillot B., Dalac S., Denis M.G, Dupuy A., Emile J.F, de la Fouchardiere A., Hindie E., Jouary T., Lassau N., Mirabel X. et al..  2017.  French updated recommendations in Stage I to III melanoma treatment and management. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 31:594-602.

Hurabielle C., Ingen-Housz-Oro S., Ortonne N., Cornillet-Lefebvre P., Merah A., d'Incan M., Joly P., Franck N., Esteve E., Maubec E. et al..  2015.  Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. BRITISH JOURNAL OF DERMATOLOGY. 173:1015-1023.

Mortier L., Saiag P., Thomas L., Lebbe C., Maubec E., Meyer N., Jouary T., Dalac S., Lesimple T., Dreno B. et al..  2016.  Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Societe Francaise de Dermatologie. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 143:559-561.

Dalle S., Mortier L., Dutriaux C., Dalac S., Leccia M., Saiag P., Dreno B., Kowal A., Allayous C., Lebbe C..  2016.  MelBase, a French national cohort dedicated to melanoma unresectable stage III and IV patients. JOURNAL OF INVESTIGATIVE DERMATOLOGY. 136:S246.

Oriano B., Dalle S., Mortier L., Dutriaux C., Dereure O., Leccia M-T., Dalac S., Legoupil D., De Quatrebarbes J., Montaudie H. et al..  2020.  Mortality prediction in real world advanced melanoma patients treated by anti-PD1 within MelBase, a French multicentric prospective cohort. ANNALS OF ONCOLOGY. 31:S751.

Mortier L., Saiag P., Thomas L., Lebbe C., Maubec E., Meyer N., Jouary T., Dalac S., Lesimple T., Dreno B. et al..  2016.  Perioral pyoderma gangrenosum revealing systemic anaplastic lymphoma in a child. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 143:561-563.

Vabres P., Sorlin A., Kholmanskikh S.S, Demeer B., St-Onge J., Duffourd Y., Kuentz P., Courcet J., Carmignac V., Bessis D. et al..  2018.  Postzygotic dominant-negative mutations of RHOA cause a mosaic neuroectodermal syndrome. EUROPEAN JOURNAL OF HUMAN GENETICS. 26:215-216.

Vabres P., Sorlin A., Kholmanskikh S.S, Demeer B., St-Onge J., Duffourd Y., Kuentz P., Courcet J., Carmignac V., Bessis D. et al..  2018.  Postzygotic dominant-negative mutations of RHOA cause a mosaic neuroectodermal syndrome. EUROPEAN JOURNAL OF HUMAN GENETICS. 26:215-216.

Di Filippo Y., Dalle S., Mortier L., Dereure O., Dalac S., Dutriaux C., Leccia M-T, Legoupil D., Saiag P., Brunet-Possenti F. et al..  2021.  Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. ANNALS OF ONCOLOGY. 32:542-551.

Kandel M., Allayous C., Dalle S., Mortier L., Dalac S., Dutriaux C., Leccia M.T, Guillot B., Saiag P., Lacour J.P et al..  2018.  Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. EUROPEAN JOURNAL OF CANCER. 105:33-40.